Lee Kyuho, Lee Kyoung-Bun, Yi Nam-Joon, Suh Kyung-Suk, Jang Ja-June
Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.
Department of Surgery, Seoul National University College of Medicine, Seoul, Korea.
J Pathol Transl Med. 2017 Jan;51(1):79-86. doi: 10.4132/jptm.2016.10.13. Epub 2016 Dec 25.
Liver transplantation (LT) is the treatment of choice for hepatocellular carcinoma (HCC). The aim of this study was to investigate the recurrence rate of HCC after LT and prognostic factors for recurrence by comparing LT with non-transplanted resection.
The participants were 338 patients who underwent LT between 1996 and 2012 at Seoul National University Hospital (LT group) and 520 HCC patients who underwent partial hepatectomy between 1995 and 2006 (control group, non-LT group).
In the LT group, 68 of 338 patients (19.8%) showed relapse, and the recurrence rate was lower than that in the non-LT group (64.9%, 357/520, p < .001). Stratification analysis by American Joint Committee on Cancer (AJCC) stage showed that the stage I-II LT group had a lower recurrence rate than the non-LT group. Univariate comparative analysis demonstrated that multiplicity of tumor, tumor size, gross type, Edmondson- Steiner (ES) nuclear grade, extent of tumor, angioinvasion, AJCC stage, Milan criteria, University of California at San Francisco criteria on explant pathology (all p < .001), positive expression of cytokeratin 19 (p = .002), and preoperative α-fetoprotein (AFP) (p < .001) were predictors of tumor recurrence. In multivariate analysis, LT, preoperative AFP, multiplicity of tumor, extent of tumor, size of tumor, and ES nuclear grade were independent prognostic factors.
LT might have a protective effect against the late recurrence of stage I-II HCC compared to non-LT, and the prognostic factors for recurrence were similar to previously well-known prognostic factors for HCC.
肝移植(LT)是肝细胞癌(HCC)的首选治疗方法。本研究旨在通过比较肝移植与非移植性肝切除术,探讨肝移植术后肝癌的复发率及复发的预后因素。
研究对象为1996年至2012年在首尔国立大学医院接受肝移植的338例患者(肝移植组)和1995年至2006年接受部分肝切除术的520例肝癌患者(对照组,非肝移植组)。
肝移植组338例患者中有68例(19.8%)出现复发,复发率低于非肝移植组(64.9%,357/520,p<.001)。美国癌症联合委员会(AJCC)分期的分层分析显示,I-II期肝移植组的复发率低于非肝移植组。单因素比较分析表明,肿瘤的多灶性、肿瘤大小、大体类型、埃德蒙森-斯坦纳(ES)核分级、肿瘤范围、血管侵犯、AJCC分期、米兰标准、加利福尼亚大学旧金山分校外植体病理学标准(均p<.001)、细胞角蛋白19的阳性表达(p=.002)和术前甲胎蛋白(AFP)(p<.001)是肿瘤复发的预测因素。多因素分析中,肝移植、术前AFP、肿瘤多灶性、肿瘤范围、肿瘤大小和ES核分级是独立的预后因素。
与非肝移植相比,肝移植可能对I-II期肝癌的晚期复发具有保护作用,复发的预后因素与既往熟知的肝癌预后因素相似。